Supriya Lifescience Q1 FY27: Revenue up, PBT down

Key update from the company

Supriya Lifescience Limited announced its unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY27). The company reported a sharp rise in revenue from operations year-on-year, while profit before tax (PBT) declined compared with the corresponding quarter last year. Alongside the results, the company also disclosed a schedule of investor engagements, including a board meeting date and an earnings call. These updates matter for investors tracking both near-term profitability and management commentary on demand, costs, and execution.

Q1 FY27 financial performance at a glance

For Q1 FY27, revenue from operations stood at ₹189.75 crore (₹1,897.47 million). This compares with ₹145.07 crore (₹1,450.74 million) in Q1 FY26, as stated in the provided information. Total income for the quarter was ₹192.40 crore (₹1,923.95 million). Total expenses were reported at ₹151.60 crore (₹1,516.03 million), resulting in PBT of ₹40.79 crore (₹407.92 million). After tax expense, net profit from continuing operations was ₹24.04 crore (₹240.43 million).

Profitability and per-share metrics

PBT declined to ₹40.79 crore in Q1 FY27 from ₹47.41 crore (₹474.12 million) in the corresponding quarter of the previous year, based on the figures provided. Total comprehensive income for the quarter was ₹24.69 crore (₹246.90 million). Earnings per equity share for continuing operations were ₹2.99 (basic and diluted). These metrics indicate that while topline expanded, profits did not move in the same direction in this quarter.

A data point that needs careful reading

The provided material also mentions a revenue comparison against ₹77.87 crore (₹778.73 million) for the quarter ended June 30, 2025. This sits alongside the separate comparison that places Q1 FY26 revenue from operations at ₹145.07 crore (₹1,450.74 million). Both figures are present in the source text, and readers should rely on the company’s official filings and the detailed financial statement notes to reconcile the base period used in different parts of the communication.

Board meeting and results review timeline

Supriya Lifescience said its board meeting to review Q1 FY27 results is scheduled for Thursday, August 13, 2026. The company also indicated that the unaudited financial results for the quarter ended June 30, 2026 will be discussed. Such board reviews typically precede wider dissemination and investor communication, and they set the stage for management’s explanation of quarterly drivers.

Earnings call: date, time, and access

The company informed stock exchanges that it will hold an earnings call to discuss operational and financial performance for Q1 FY27. The call is scheduled for Friday, August 14, 2026 at 11:00 AM IST. Dial-in numbers shared include +91 22 6280 1107 and +91 22 7115 8008, with additional access numbers for Hong Kong, Singapore, the USA, and the UK. The company also noted that an investor presentation would be shared with the exchanges separately.

Investor interactions held in June 2026

Separately from the results call, Supriya Lifescience disclosed virtual investor engagements in June 2026. One virtual group meeting was scheduled for Friday, June 12, 2026 from 10:00 AM to 11:00 AM as part of the Choice Institutional Equities Virtual Investor Conference. Another virtual group meeting was scheduled for June 18, 2026 from 2:00 PM to 3:00 PM, with interaction planned with Kotak PCG clients and institutional investors. The company stated that schedules are subject to change due to exigencies.

Dividend and investor information disclosures

The provided text also references a final dividend of Re. 1.00 per share. In addition, investor relations contacts from EY were mentioned, along with corporate office and factory addresses. Such disclosures are typically included in exchange communications to help investors access materials and connect with the company through formal channels.

Market snapshot mentioned in the material

The data shared includes a cited current share price of ₹922.85, and elsewhere ₹928. It also lists a market cap of about ₹5.5K crore and a P/E ratio of 29.9. These numbers provide context for how the market is valuing the business around the time of the results-related disclosures.

Key numbers table (normalized to ₹ crore)

Events and disclosures timeline

Market impact and what investors will watch

The quarter’s headline is a strong rise in revenue from operations alongside weaker PBT versus the comparable quarter, based on the stated numbers. For investors, the earnings call becomes important because it is the main forum where management typically addresses the gap between topline growth and profitability. With expenses disclosed at ₹151.60 crore against total income of ₹192.40 crore, the cost structure and mix of revenue are likely to be key discussion points, though the provided text does not break down the drivers. Investors may also track follow-up filings such as the investor presentation that the company said would be shared separately.

Conclusion

Supriya Lifescience reported Q1 FY27 revenue from operations of ₹189.75 crore, while PBT came in at ₹40.79 crore, lower than the comparable prior-year quarter figure provided. The company has lined up a board review on August 13, 2026 and an earnings call on August 14, 2026 to discuss the quarter. The next set of disclosures, including the promised investor presentation and management commentary on the call, will provide further clarity on quarterly performance and operational priorities.